Alison Boyle

463 total citations · 1 hit paper
11 papers, 264 citations indexed

About

Alison Boyle is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Alison Boyle has authored 11 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hepatology, 3 papers in Infectious Diseases and 3 papers in Epidemiology. Recurrent topics in Alison Boyle's work include Hepatitis C virus research (4 papers), Drug-Induced Hepatotoxicity and Protection (3 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (2 papers). Alison Boyle is often cited by papers focused on Hepatitis C virus research (4 papers), Drug-Induced Hepatotoxicity and Protection (3 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (2 papers). Alison Boyle collaborates with scholars based in United Kingdom, Switzerland and Netherlands. Alison Boyle's co-authors include Saye Khoo, Catia Marzolini, Fiona Marra, Sara Gibbons, David Back, David M. Burger, Anton Pozniak, Marta Boffito, Daniel R. Kuritzkes and Laura Waters and has published in prestigious journals such as Journal of Hepatology, Clinical Pharmacology & Therapeutics and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Alison Boyle

8 papers receiving 260 citations

Hit Papers

Recommendations for the Management of Drug–Drug Interacti... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
    2022 162 citations Catia Marzolini, Daniel R. Kuritzkes et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alison Boyle United Kingdom 5 168 46 42 35 34 11 264
Bahman Amani Iran 10 296 1.8× 37 0.8× 65 1.5× 24 0.7× 33 1.0× 27 462
Maria Garcia‐Cremades United States 9 141 0.8× 42 0.9× 43 1.0× 13 0.4× 19 0.6× 17 232
Jiake Tang China 7 221 1.3× 99 2.2× 55 1.3× 14 0.4× 36 1.1× 22 407
Abdul Samad Ansari India 5 232 1.4× 65 1.4× 62 1.5× 14 0.4× 42 1.2× 10 391
Rohit Rao United States 9 89 0.5× 64 1.4× 37 0.9× 18 0.5× 28 0.8× 19 239
Frances Hackman United Kingdom 8 118 0.7× 24 0.5× 50 1.2× 22 0.6× 30 0.9× 9 239
R Cvetković New Zealand 6 278 1.7× 68 1.5× 91 2.2× 38 1.1× 28 0.8× 10 543
Jiandan Qian China 4 284 1.7× 33 0.7× 41 1.0× 20 0.6× 41 1.2× 8 374
Deepak Talwar India 8 240 1.4× 72 1.6× 72 1.7× 13 0.4× 42 1.2× 60 536
Eugene P. Kadar United States 9 118 0.7× 14 0.3× 75 1.8× 47 1.3× 61 1.8× 16 302

Countries citing papers authored by Alison Boyle

Since Specialization
Citations

This map shows the geographic impact of Alison Boyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Boyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Boyle more than expected).

Fields of papers citing papers by Alison Boyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Boyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Boyle. The network helps show where Alison Boyle may publish in the future.

Co-authorship network of co-authors of Alison Boyle

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Boyle. A scholar is included among the top collaborators of Alison Boyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Boyle. Alison Boyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Marzolini, Catia, Daniel R. Kuritzkes, Fiona Marra, et al.. (2022). Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clinical Pharmacology & Therapeutics. 112(6). 1191–1200. 162 indexed citations breakdown →
3.
4.
Marra, Fiona, Elise J. Smolders, Omar El‐Sherif, et al.. (2020). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs in R&D. 21(1). 9–27. 39 indexed citations
5.
6.
Hodge, Daryl, Fiona Marra, Catia Marzolini, et al.. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. Journal of Antimicrobial Chemotherapy. 75(12). 3417–3424. 25 indexed citations
7.
Boyle, Alison, Fiona Marra, T. Ritchíe, et al.. (2019). Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. Journal of Viral Hepatitis. 27(4). 371–375. 4 indexed citations
8.
Boyle, Alison, et al.. (2019). Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. Clinical Pharmacokinetics. 58(12). 1553–1565. 26 indexed citations
9.
10.
11.
Boyle, Alison, et al.. (2011). Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years. Journal of Critical Care. 27(3). 320.e7–320.e12. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bahman Amani Breakdown of academic impact, for papers by Maria Garcia‐Cremades Breakdown of academic impact, for papers by Jiake Tang Breakdown of academic impact, for papers by Abdul Samad Ansari Breakdown of academic impact, for papers by Rohit Rao Breakdown of academic impact, for papers by Frances Hackman Breakdown of academic impact, for papers by R Cvetković Breakdown of academic impact, for papers by Jiandan Qian Breakdown of academic impact, for papers by Deepak Talwar Breakdown of academic impact, for papers by Eugene P. Kadar
Rankless by CCL
2026